Reduced inflammation of PCR-proven CMV Anterior Uveitis with recurrence after anti-CMV treatment: Case Series
Purpose
To describe the features of PCR-proven CMV anterior uveitis with recurrence after oral or topical anti-CMV treatment for 4-6 months
Methods
Twenty-eight eyes with PCR-proven CMV anterior uveitis were treated with either 2% topical ganciclovir or oral valganciclovir 900mg/day for 4-6 months. Resolution of inflammation was demonstrated immediately in all 28 eyes.
Results
Three (10.7%) cases of CMV anterior uveitis with recurrence were demonstrated after complete anti-CMV treatment. One case was treated with 2% topical ganciclovir initially and then 6-month oral valganciclovir therapy. Another 2 cases were treated with 6-month oral valganciclovir treatment. Recurrence with IOP elevation and/or presence of KPs occurred after initial oral therapy 4-6 months. However, compared to the baseline presentation, recurrence after oral valganciclovir treatment revealed less fulminant. The level of IOP elevation was from 56 13 at baseline to 26 8 with recurrence, and the amount of KPs is from 50-100 at baseline to 10-25 with recurrence at least 9-month follow-up. All recurrence was well-controlled with topical antihypertensive and anti-inflammatory agents.
Conclusion
Recurrence of CMV anterior uveitis still occurred after 6-month oral valganciclovir treatment. Reduced IOP elevation and less inflammation were demonstrated during recurrence of CMV anterior uveitis after systemic anti-CMV treatment.
Conflict of interest
No
Authors 1
Last name
PENG
Initials of first name(s)
CH
Department
Department of Ophthalmology, Shin-Kong Wu Ho-Su Memorial Hospital
City
Taipei
Country
Taiwan
Authors 2
Last name
Liang
Initials of first name(s)
YT
Department
Department of Ophthalmology, Shin-Kong Wu Ho-Su Memorial Hospital
City
Taipei
Country
Taiwan
This website uses cookies to ensure you get the best experience on our website.
Learn more